Sanford C. Bernstein set a €129.00 ($153.57) price objective on Bayer (FRA:BAYN) in a research report report published on Wednesday. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other research analysts have also recently weighed in on BAYN. UBS Group set a €125.00 ($148.81) price target on shares of Bayer and gave the stock a buy rating in a research note on Thursday, December 7th. Barclays set a €100.00 ($119.05) price target on shares of Bayer and gave the stock a sell rating in a research note on Tuesday, December 12th. Commerzbank set a €124.00 ($147.62) price target on shares of Bayer and gave the stock a buy rating in a research note on Wednesday, November 15th. Nord/LB set a €102.00 ($121.43) price target on shares of Bayer and gave the stock a neutral rating in a research note on Friday, December 8th. Finally, Berenberg Bank set a €124.00 ($147.62) price target on shares of Bayer and gave the stock a neutral rating in a research note on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of €121.71 ($144.90).
Shares of Bayer (FRA BAYN) opened at €104.08 ($123.90) on Wednesday. Bayer has a 1 year low of €100.60 ($119.76) and a 1 year high of €123.82 ($147.40). The company has a market cap of $86,000.00 and a P/E ratio of 27.90.
TRADEMARK VIOLATION NOTICE: “Bayer (BAYN) PT Set at €129.00 by Sanford C. Bernstein” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/21/bayer-bayn-pt-set-at-129-00-by-sanford-c-bernstein.html.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.